Pomalidomide, Anti-PD-1 Antibody Combined With Selinexor (PPS) in Relapsed/Refractory Primary Central Nervous System Diffuse Large B-Cell Lymphoma

NCT07523737 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

43

Enrollment

OTHER

Sponsor class

Conditions

Primary Central Nervous System Lymphoma (PCNSL)
Diffuse Large B Cell Lymphoma (DLBCL)

Interventions

DRUG: Pomalidomide
DRUG: PD-1 / PD-L1 monoclonal antibody
DRUG: XPO1 inhibitor

Sponsor

Beijing Tongren Hospital